Luke Evnin Sells 305,741 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the sale, the director owned 1,273,008 shares in the company, valued at approximately $891,105.60. This represents a 19.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $22,745.16.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total value of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $0.58 on Thursday. The firm has a market cap of $28.38 million, a P/E ratio of -0.47 and a beta of 0.41. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $2.38. The business’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.83.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its holdings in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the last quarter. Regal Investment Advisors LLC grew its stake in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on HOWL shares. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.